Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$6.55 - $20.22
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$2.71B
Enterprise Value$1.57K
Total Cash (Recent Filing)$171.78M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding141,979,700
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.86Price Target Upside84.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage; Strong Balance SheetA near-zero debt-to-equity ratio and meaningful asset base provide durable financial flexibility for multi-year clinical programs. Low leverage reduces refinancing and interest risks, enabling Trevi to prioritize development spending and strategic choices without immediate debt pressure.
Pro Forma Cash Runway Into 2030Substantial pro forma cash balances materially de-risk near-term funding needs for pivotal trials and regulatory interactions. A multi-year runway supports planned Phase III and Phase IIb starts, lowering likelihood of near-term dilutive raises and allowing focus on execution toward potential approval.
Meaningful Intellectual Property ProtectionIssued patents through 2039 and pending U.S. filings that may extend to 2046 create a durable competitive moat. Strong IP positioning supports future commercialization leverage, potential partnering value and longer-term exclusivity for Haduvio if clinical/regulatory success is achieved.
Bears Say
Pre-revenue; Persistent Net LossesAbsence of product revenue means value depends entirely on clinical success and eventual commercialization. Continued sizable net losses reflect that returns on capital are negative today and that shareholder value is contingent on successful trials and regulatory approval over multiple years.
Ongoing Cash Burn; Negative Operating Cash FlowMaterial negative operating and free cash flow indicate recurring funding needs; while burn improved, sustained deficits require future financing to support later-stage trials or a launch. This structural cash gap can dilute equity or constrain strategic options absent partnerships.
Trial Upsizing Risk Raising Costs And TimelinesAdaptive/sample-size reestimation designs create execution risk: failing conditional-power thresholds can force larger samples and longer trials. That elevates development cost and timing uncertainty, stressing cash runway and complicating planning for regulatory submissions and commercialization.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $6.55 and its highest was $20.22 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $2.71B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.014.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.11.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 141,979,700 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.86 (84.54% Upside)
$24.86 (84.54% Upside)
Hedge Fund Trend
Increased
By 326.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.9%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
67.85%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
TRVI Stock 12 Month Forecast
Average Price Target
$24.86
▲(84.54% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.32% Insiders
16.81% Mutual Funds
2.37% Other Institutional Investors
69.14% Public Companies and
Individual Investors